Roivant Sciences Future Growth
Future criteria checks 2/6
Roivant Sciences is forecast to grow earnings and revenue by 21.3% and 55% per annum respectively. EPS is expected to grow by 18.5% per annum. Return on equity is forecast to be -17% in 3 years.
Key information
21.3%
Earnings growth rate
18.5%
EPS growth rate
| Biotechs earnings growth | 24.0% |
| Revenue growth rate | 55.0% |
| Future return on equity | -17.0% |
| Analyst coverage | Good |
| Last updated | 17 Apr 2025 |
Recent future growth updates
Recent updates
Roivant Sciences: Primed For Growth With A De-Risked Pipeline
Apr 23Industry Analysts Just Upgraded Their Roivant Sciences Ltd. (NASDAQ:ROIV) Revenue Forecasts By 21%
Feb 12
Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)
Feb 05
Late-stage Trials For Brepocitinib And Batoclimab Will Unlock Potential, But Execution Risks Remain
Jan 26 Successful clinical trials and strategic deals may improve revenue and net margins by focusing on high-value areas.Roivant Sciences: A Biotech Growth Play With Major Ambitions
Dec 04Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility
Oct 22Statutory Earnings May Not Be The Best Way To Understand Roivant Sciences' (NASDAQ:ROIV) True Position
Aug 22Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses
Aug 22Roivant Sciences: Executing On Huge Buyback Program With More To Come
Jun 02Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success
Mar 18Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2028 | 559 | -730 | N/A | N/A | 4 |
| 3/31/2027 | 51 | -998 | -852 | -845 | 7 |
| 3/31/2026 | 25 | -840 | -816 | -810 | 7 |
| 3/31/2025 | 141 | -106 | -238 | -233 | 6 |
| 12/31/2024 | 123 | -717 | -779 | -775 | N/A |
| 9/30/2024 | 129 | 4,595 | -781 | -779 | N/A |
| 6/30/2024 | 128 | 4,564 | -710 | -708 | N/A |
| 3/31/2024 | 125 | 4,349 | -767 | -765 | N/A |
| 12/31/2023 | 51 | 4,579 | -839 | -836 | N/A |
| 9/30/2023 | 53 | -927 | -851 | -848 | N/A |
| 6/30/2023 | 61 | -1,001 | -987 | -841 | N/A |
| 3/31/2023 | 61 | -1,124 | -996 | -843 | N/A |
| 12/31/2022 | 43 | -1,245 | -969 | -812 | N/A |
| 9/30/2022 | 50 | -1,178 | -1,021 | -858 | N/A |
| 6/30/2022 | 52 | -1,095 | -811 | -789 | N/A |
| 3/31/2022 | 55 | -845 | -695 | -678 | N/A |
| 12/31/2021 | 61 | -1,085 | -652 | -636 | N/A |
| 9/30/2021 | 43 | -1,061 | -614 | -605 | N/A |
| 6/30/2021 | 30 | -888 | -590 | -582 | N/A |
| 3/31/2021 | 24 | -809 | -558 | -552 | N/A |
| 12/31/2020 | 72 | -360 | -535 | -531 | N/A |
| 3/31/2020 | 68 | -456 | -764 | -759 | N/A |
| 3/31/2019 | 2 | -613 | -1,035 | -1,024 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ROIV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ROIV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ROIV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ROIV's revenue (55% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: ROIV's revenue (55% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ROIV is forecast to be unprofitable in 3 years.
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/11 01:21 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Roivant Sciences Ltd. is covered by 16 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Chi Meng Fong | BofA Global Research |
| Louise Chen | Cantor Fitzgerald & Co. |